Immunological and biochemical modulation in the treatment of advanced colorectal cancer: update and future directions.
Hilgenfeld
R U
RU
Medical Department I, St. Joseph Hospital, Berlin, Germany.
Kreuser
E D
ED
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000145:classification / Q000627:therapeutic use*; D010478:Chemotherapy, Cancer, Regional Perfusion; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D004621:Embolization, Therapeutic; D006499:Hepatic Artery; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy; D007261:Infusions, Intra-Arterial; D007372:Interferons / Q000627:therapeutic use; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D010166:Palliative Care; D011379:Prognosis; D011788:Quality of Life; D059004:Topoisomerase I Inhibitors
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D009363:Neoplasm Proteins; D059004:Topoisomerase I Inhibitors; D007372:Interferons